Publication | Open Access

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

UrologyOncologyGenitourinary Cancer177Lu-psma-617 VersusMedicineCancer TreatmentProstatic DiseasePharmacologyMolecular OncologyPhase 3Taxane-naive Patients